Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO
September 16, 2021 18:25 ET
|
Agenus Inc.
Objective response rate of 33% and median duration of response not reached with 19.4 months median follow-up in PD-L1+ tumors; expands benefit of anti-PD-1 aloneImproved responses seen across all...
New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
September 10, 2021 07:30 ET
|
Agenus Inc.
LEXINGTON, Mass. and BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and...
Agenus to Participate in September Investor Conferences
September 09, 2021 08:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Balstilimab Monotherapy Data Published in Gynecologic Oncology
August 26, 2021 09:00 ET
|
Agenus Inc.
Objective response rate of 20% and median duration of response not reached with 14.6 month median follow-up in PD-L1+ tumorsResponses seen across all histology subgroups including populations of...
Agenus Corporate Update and Second Quarter 2021 Financial Report
August 09, 2021 07:45 ET
|
Agenus Inc.
$200M received from BMS for anti-TIGIT bispecific antibody collaborationFDA cleared IND for AGEN1777 clinical enrollmentAGEN1181 rapidly advancing in the clinic; data to be presented in 2H 2021Cell...
Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021
August 02, 2021 16:05 ET
|
Agenus Inc.
LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
MiNK Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
July 28, 2021 08:30 ET
|
Agenus Inc.
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange...
Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report
July 26, 2021 16:05 ET
|
Agenus Inc.
LEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021
July 07, 2021 16:05 ET
|
Agenus Inc.
LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777
July 06, 2021 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies,...